Amgen Wins FDA Approval for Shorter Imdelltra Monitoring

Amgen announced that the US Food and Drug Administration approved an update to the prescribing label for its cancer immunotherapy Imdelltra. The regulatory change substantially shortens the observation requirement for the drug's first two infusions.

Under the revised guidance, healthcare teams must monitor patients for 6 to 8 hours from the start of the first two infusions. The previous standard required 22 to 24 hours of observation. Patients will also receive a follow-up assessment with vital signs the day after each of those initial doses.

Imdelltra treats adults with extensive-stage small cell lung cancer who experienced disease progression on or after platinum chemotherapy. Amgen noted that an estimated 80% to 85% of US cancer patients receive care in community oncology practices, where shorter stays may lower delivery hurdles.

Monitoring schedules for later cycles remain unchanged, staying at 6 to 8 hours for the third dose and Cycle 2, 3 to 4 hours for Cycles 3 and 4, and 2 hours from Cycle 5 onward. Patients must still stay within 1 hour of a care setting for 48 hours following the first two infusions.